Neurodegenerative Diseases Initiative

Neurodegenerative diseases are a group of progressive, incurable disorders characterized by the gradual loss of structure or function of neurons in the brain and spinal cord.

Phase I
Systems Architecture
Systems Architecture
Status: Completed
The Systems Architecture of Neurodegenerative Diseases is published as a web based tool open to public.
Phase II
Publications
Publications
Status: Completed
A peer-reviewed paper was published in 2016 in NATURE’s Neuroscience journal.
Phase III
In Silico Modeling
In Silico Modeling
Status: In Progress
In this phase, in silico modeling will develop mathematical models of Neurodegenerative Diseases pathogenesis. This phase is in progress.
Phase IV
Combination Screening
Combination Screening
Status: Open
Combination Screening will be conducted to identify compounds targeting biological processes in Neurodegenerative Diseases pathogenesis.
Phase V
Patents
Patents
Status: Open
In this phase, a US patent will be filed for the newly discovered combination(s).
Phase VI
Licensing and Manufacturing
Licensing and Manufacturing
Status: Open
The Osteoarthritis Initiative will license and manufacture nutraceuticals to support treatment of Neurodegenerative Diseases.

Background on Neurodegenerative Diseases

Neurodegenerative diseases are a group of progressive, incurable disorders characterized by the gradual loss of structure or function of neurons in the brain and spinal cord. Common examples include Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and Amyotrophic Lateral Sclerosis (ALS). These conditions often lead to cognitive decline, memory loss, impaired movement, and in severe cases, complete loss of independence. The underlying cause of neurodegeneration varies by disease but typically involves the accumulation of abnormal proteins in the brain, oxidative stress, mitochondrial dysfunction, inflammation, and genetic mutations. For example, Alzheimer’s disease is linked to the build-up of beta-amyloid plaques and tau tangles, while Parkinson’s disease is associated with the loss of dopamine-producing neurons in the substantia nigra. Symptoms can progress slowly, making early detection challenging. Patients may experience subtle memory lapses, mood changes, motor difficulties, or speech problems. As the disease advances, quality of life declines, and intensive care becomes necessary. Although no cure currently exists, treatments focus on managing symptoms and slowing disease progression. Approaches include medications, physical therapy, dietary support, and in some cases, experimental therapies like stem cells or gene editing. Research is ongoing to uncover the molecular mechanisms of neurodegeneration and discover new treatment options. Preventive strategies such as a healthy diet, regular exercise, cognitive engagement, and managing chronic conditions (like diabetes and hypertension) may reduce risk. Understanding and addressing neurodegenerative diseases is crucial for aging populations and global public health.

Systems Architecture

The Systems Architecture of Neurodegenerative diseases is published as a Web-based tool open to public. This phase is yet to begin.

Publication

A peer-reviewed paper was published in 2016 in the journal Nature Neuroscience.

In Silico Modeling

In this phase, the Neurodegenerative diseases Initiative will conduct in silico modeling to identify and test the efficacy of compounds on neurodegenerative diseases. This phase is yet to begin.

Combination Screening

In this phase, combination screening will be performed to identify potential ingredient/compounds that target the biological process implicated in Neurodegenerative pathogenesis. This phase is yet to begin.

Patents

The Open Science Institute® through its Neurodegenerative diseases initiative is moving towards getting patents for a revolutionary compounds that affects Neurodegenerative diseases.

Licensing and Manufacturing

The Neurodegenerative diseases Initiative plans to discover, develop, license and manufacture a Brain Health product which supports treatment of many diseases. Support our mission to bring this innovation to those who need it most. Please support this Phase by donating to the Neurodegenerative diseases Initiative

Health-product-label-09-10-2025